The world of REMAP-CAP is constantly evolving, here’s what’s new!

REMAP-CAP, a groundbreaking trial that has most recently been primarily focused on finding treatments for COVID-19, has now been selected by the National Institute for Healthcare and Research to evaluate therapeutic interventions for influenza.

New results have recently been published from the ACE2 RAS domain, one of the multiple therapeutic domains within REMAP-CAP, a trial within Spiral’s manifest of studies.

Spiral talks with Ly-Mee Yu, Lead Statistician of the PANORAMIC Trial on the devastating effects of the pandemic and how trials like PANORAMIC, with the help of Spiral’s software, are aiming to provide better health outcomes for those affected by the virus.

New results are in for the ASCOT Trial (Australasian Covid-19 Trial), another study in Spiral’s manifest of platform trials. This platform trial was set up to evaluate 3 different treatment approaches for effectiveness against COVID-19. Each of these approaches is called a 'domain'. The findings from the anticoagulation domain have recently been published in the New England Journal of Medicine Evidence.